MedTrace Logo

Intraperitoneal Bupivacaine With Magnesium or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy

NCT03393572 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-07-16

No results posted yet for this study

Summary

The purpose of this study is to compare between the addition of Mg sulphate or Nalbuphine to intraperitoneal bupivacaine installation in laparoscopic hysterectomy for postoperative pain control and their relative adverse effects.

Conditions

  • Anesthesia

Interventions

DRUG

Bupivacaine 0.25%

Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%

DRUG

Magnesium sulphate.

Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.

DRUG

nalbuphine

Patients will receive intraperitoneal 5 mg nalbuphine

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-03
Primary Completion
2018-06-05
Completion
2018-06-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03393572 on ClinicalTrials.gov